THE Australian Competition &
Consumer Commission (ACCC) should
explore the scope for ‘meaningful
penalties’ which could be included
in the Medicines Australia Code of
Conduct, 17th edition.
The comments come as part of a
submission to the ACCC regarding
the updated Code from Bruce
Arnold, Lecturer at the University
of Canberra’s School of Law.
“It is clear that leading
corporations that are expected to
participate in the Code have
engaged in egregious bad practice
(signalled for example by the recent
multi-billion dollar settlement in
the US
involving GlaxoSmithKline),” he ...
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 06 Aug 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
